Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnésia Bisurada is an over-the-counter (OTC) antacid medication marketed by Aspen Pharmacare, primarily in the Brazilian market. Originally developed by Pfizer and acquired by Aspen in 2019, the product is a well-established brand in the consumer healthcare segment for the symptomatic relief of gastric hyperacidity. The formulation typically consists of a combination of small molecule antacid agents, including calcium carbonate, magnesium carbonate, and sodium bicarbonate. These active ingredients work by chemically neutralizing hydrochloric acid in the stomach, thereby increasing gastric pH and providing rapid relief from symptoms such as heartburn (pyrosis), acid indigestion, and stomach pain. It is part of Aspen's portfolio of post-patent, branded medicines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Magnésia Bisurada.